Abstract
Chronic lymphocytic leukemia (CLL) is an archetype of malignancy resulting from defects in apoptosis. CLL is an exclusive accumulative disorder marked by low proliferative activity and gradual accumulation of clonal B-lymphocytes blocked in the early (G0, G1) phases of the cell cycle. The heterogeneous clinical course indicates diverse in vivo biology of the leukemic cell and suggests that CLL represents diverse behavior. Understanding the molecular biology of the disease has provided insight into the mechanisms that promote tumorigenesis, specifically defective apoptotic signaling pathways. In this review we attempt to provide a comprehensive discussion of CLL including the origin of malignant lymphocytes, the apoptotic defects and the mechanisms leading to disease progression. We further discuss the therapeutic options, focusing mainly on targeted therapy using novel agents. Finally, we suggest future directions for treatment that utilize the understanding of the disease biology.
Keywords: chronic lymphocytic leukemia, apoptosis, signal transduction, targeted therapy, molecular signatures, resistance, Chemotherapy, death pathways, transcription factors, cell survival
Current Drug Delivery
Title: Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Volume: 9 Issue: 1
Author(s): Aisha Masood, Mohammad A. Shahshahan and Ali R. Jazirehi
Affiliation:
Keywords: chronic lymphocytic leukemia, apoptosis, signal transduction, targeted therapy, molecular signatures, resistance, Chemotherapy, death pathways, transcription factors, cell survival
Abstract: Chronic lymphocytic leukemia (CLL) is an archetype of malignancy resulting from defects in apoptosis. CLL is an exclusive accumulative disorder marked by low proliferative activity and gradual accumulation of clonal B-lymphocytes blocked in the early (G0, G1) phases of the cell cycle. The heterogeneous clinical course indicates diverse in vivo biology of the leukemic cell and suggests that CLL represents diverse behavior. Understanding the molecular biology of the disease has provided insight into the mechanisms that promote tumorigenesis, specifically defective apoptotic signaling pathways. In this review we attempt to provide a comprehensive discussion of CLL including the origin of malignant lymphocytes, the apoptotic defects and the mechanisms leading to disease progression. We further discuss the therapeutic options, focusing mainly on targeted therapy using novel agents. Finally, we suggest future directions for treatment that utilize the understanding of the disease biology.
Export Options
About this article
Cite this article as:
Masood Aisha, A. Shahshahan Mohammad and R. Jazirehi Ali, Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL), Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798376050
DOI https://dx.doi.org/10.2174/156720112798376050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews When and How Should We Cover Patients for Community-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia?
Current Respiratory Medicine Reviews Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design An Efficient Synthesis of 7,11-diarylspiro[5.5]undecane-1,9-dione by the Michael Condensation Under Ultrasound Irradiation in Aqueous and Organic Two Phase in the Presence of Phase-Transfer Catalyst
Letters in Organic Chemistry Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Synthetic Approaches to Heterocyclic Guanidines with Biological Activity: An Update
Current Organic Chemistry Chest Pain in Children
Current Pediatric Reviews Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Arterial Hypertension in Current Medical Practice in Algeria
Current Hypertension Reviews Pathogenesis and Management of Intradialytic Hypertension
Current Hypertension Reviews Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action
Current Hypertension Reviews Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology